Emerging medicinal use On one July, 2023, the Therapeutic Products Administration amended its scheduling of copyright substances to enable the prescription of psilocybin to be used in copyright assisted psychotherapy for treatment-resistant despair. Trials as to their effectiveness and basic safety in dealing with different psychiatric disorders a